Core Viewpoint - Hai Li Biological (603718.SH) announced that its subsidiary, Ruisheng Biological, received approval from the Indonesian Ministry of Health (MOH) for its GORORISE Natural Bone Grafting Material, indicating a significant milestone in expanding its product offerings in the Southeast Asian market [1] Group 1: Product Development and Approval - Ruisheng Biological submitted the registration application for GORORISE Natural Bone Grafting Material to the Indonesian MOH in August 2025 [1] - The GORORISE product is an animal-derived bone repair material that closely resembles human natural bone tissue in composition and microstructure [1] - The product is designed for maxillary bone defect repair and promotes new bone generation through its interconnected porous structure and natural components, showcasing strong potential for clinical application and market expansion [1] Group 2: Regulatory Milestones - GORORISE Natural Bone Grafting Material received its Class III medical device registration certificate from the National Medical Products Administration of China in December 2013 [1] - The product also obtained a Class D medical device registration certificate in Indonesia in December 2025 [1]

本次获得印度尼西亚注册证的GORORISE天然骨移植材料是瑞盛生物研发和生产的一种动物源性骨修复 材料，在组成成分和微观结构上均与人体天然骨组织高度相似。 海利生物（603718）(603718.SH)公告，公司控股子公司陕西瑞盛生物科技有限公司(简称"瑞盛生物")于 2025年8月向印度尼西亚卫生部(简称"MOH")递交了瑞盛生物GORORISE Natural Bone Grafting Material(GORORISE天然骨移植材料)产品的注册申报资料。瑞盛生物于近日收到MOH通知，瑞盛生物 的GORORISE天然骨移植材料产品获得MOH的批准。 ...

本次获得印度尼西亚注册证的GORORISE天然骨移植材料是瑞盛生物研发和生产的一种动物源性骨修复 材料，在组成成分和微观结构上均与人体天然骨组织高度相似。 智通财经APP讯，海利生物(603718.SH)公告，公司控股子公司陕西瑞盛生物科技有限公司(简称"瑞盛生 物")于2025年8月向印度尼西亚卫生部(简称"MOH")递交了瑞盛生物GORORISE Natural Bone Grafting Material (GORORISE天然骨移植材料)产品的注册申报资料。瑞盛生物于近日收到MOH通知，瑞盛生物 的GORORISE天然骨移植材料产品获得MOH的批准。 ...